Welcome to our dedicated page for Zoetis SEC filings (Ticker: ZTS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Zoetis Inc. (ZTS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Zoetis, described as the world’s leading animal health company, uses filings such as Form 8-K to report material events related to its operations, financing activities, governance and shareholder returns.
Recent 8-K filings detail several types of information. Zoetis has reported the completion of a private offering of 0.25% Convertible Senior Notes due 2029, including the terms of the notes, their conversion features, optional redemption provisions and related capped call transactions. Other filings describe the issuance of senior notes due 2028 and 2035 under an existing indenture, as well as a revolving credit agreement that provides a senior unsecured revolving credit facility and replaces a prior credit agreement.
Filings also cover corporate actions affecting shareholders, such as declarations of cash dividends on Zoetis common stock and the use of proceeds from financing transactions to repurchase shares under an existing share repurchase program. Additional 8-Ks report quarterly financial results, guidance updates, and investor presentations, including an Innovation Webcast that outlines the company’s pipeline and strategic approach to addressing unmet medical needs in animals.
Through this page, users can review how Zoetis discloses information about its NYSE-listed common stock, debt obligations, credit facilities and board-level decisions. Stock Titan’s platform associates these filings with AI-powered tools that summarize key terms and highlight items such as note covenants, leverage provisions, dividend declarations and event-driven disclosures, helping readers interpret lengthy documents more efficiently.
Zoetis Inc. director Mark Stetter reported receiving a grant of 215.5358 phantom stock units linked to Zoetis common stock. These units were acquired under the Zoetis Inc. Amended and Restated Non-Employee Director Deferred Compensation Plan as a deferral of his cash retainer fees into the Zoetis stock fund, including dividend equivalents. Each phantom stock unit represents one share of Zoetis common stock but will be settled in cash after his separation from service, so this is a compensation and deferral event rather than an open-market stock purchase or sale.
Zoetis Inc. director Gregory Norden reported a bona fide gift of 1,213 shares of Zoetis common stock on March 9, 2026. The shares were transferred to a trust for which he serves as trustee. Following this transfer, he holds Zoetis shares indirectly through personal and family trusts.
Zoetis Inc. director Michael B. McCallister reported equity award activity involving restricted stock units (RSUs) and common shares. On February 19, he exercised RSUs covering 1,619.3325 units at a price of $0.00 per unit, receiving 1,619 common shares. A separate entry shows 413 common shares transferred to Zoetis in exchange for cash based on the $127.28 closing share price on the vesting date. After these transactions, he directly held 1,209 common shares and 1,936 RSUs, with additional indirect holdings of 21,524 and 6,160 common shares held by family trusts.
Zoetis Inc. director Gregory Norden reported equity award activity involving restricted stock units (RSUs) and common shares. He exercised or converted 1,619.3325 RSUs, resulting in the acquisition of 1,619 common shares of Zoetis stock at a stated price of $0.00 per share, reflecting settlement of equity awards rather than an open-market purchase.
As part of the same event, 406 common shares were disposed of back to Zoetis in exchange for cash based on the closing share price of $127.28 per share on the vesting date, typically to cover obligations such as taxes. After these transactions, Norden directly held 1,213 common shares and 1,936 RSUs, and also had indirect ownership through a personal trust and separate trusts for his daughter and son, which together hold several thousand additional Zoetis common shares.
Zoetis Inc. director Vanessa Broadhurst reported equity compensation activity involving restricted stock units (RSUs) and common shares. On February 19, 2026, RSUs covering about 1,619 shares were exercised and converted into 1,619 shares of Zoetis common stock at a price of $0.00 per share. A separate transaction involving 517 common shares at $127.28 per share was reported as an other acquisition or disposition, with a footnote explaining these shares were transferred back to Zoetis in exchange for cash based on the closing share price on the vesting date. After these movements, she directly holds 3,920 shares of Zoetis common stock and 1,936 RSUs that each represent a contingent right to receive one share of common stock, generally vesting on the first anniversary of the grant date if service conditions are met.
Zoetis Inc. Executive Vice President Julie Fuller reported equity award activity tied to restricted stock units (RSUs). On February 19, 2026, RSUs converted into 750 shares of common stock at a stated price of $0.0000 per share, reflecting vesting and settlement of RSUs. On the same date, 290 common shares were disposed of at $127.2800 per share to cover tax obligations through a tax-withholding disposition. Footnotes explain that each RSU represents a right to receive one Zoetis common share, with one-third of each RSU grant generally vesting on each of the first, second, and third anniversaries of the grant dates, subject to continued service and certain earlier vesting events.
Zoetis Inc. Chief Financial Officer Joseph Wetteny reported equity compensation activity involving restricted stock units (RSUs) and common shares on February 19, 2026. RSUs representing 2,050.6517 units were exercised and converted, resulting in the acquisition of 2,050 common shares at a stated price of $0.00 per share as part of vesting and settlement.
To satisfy tax obligations tied to this vesting, 703 common shares were disposed of at $127.28 per share through tax withholding. After these transactions, Wetteny directly owned 22,113 shares of Zoetis common stock. He also held outstanding RSU awards that, after the reported activity, totaled 8,605 RSUs and 1,389 RSUs under separate grants, each generally vesting in one‑third increments on the first, second, and third anniversaries of their respective grant dates, subject to continued service and certain earlier‑vesting events.
Zoetis Inc. Chief Executive Officer Kristin C. Peck reported equity award activity involving restricted stock units (RSUs) and common stock. On February 19, 2026, RSUs converted into 7,354 shares of Zoetis common stock at no cost, increasing her directly held common stock to 108,691 shares before tax-related withholding.
On the same date, 3,623 common shares were withheld at $127.28 per share to cover tax obligations tied to the vesting, leaving 105,068 common shares held directly afterward. She also holds RSUs totaling 28,072 and 5,556 units that each represent a contingent right to one Zoetis share, plus 833.6435 common stock equivalents in the Zoetis 401(k) Savings Plan as of December 31, 2025.
Zoetis Inc. Executive Vice President Nicholas Ashton reported equity award activity involving restricted stock units (RSUs) and common shares. On February 19, he acquired 750 shares of Zoetis common stock at $0.0000 per share through the exercise and settlement of RSUs, with 2,214 common shares held directly after this step.
On the same date, 392 common shares at $127.2800 per share were disposed of to satisfy tax withholding obligations related to the vesting event, leaving 1,822 common shares held directly. Footnotes explain that each RSU converts into one Zoetis common share and vests in three annual installments following the original grant dates, subject to continued service and certain specified events.
Zoetis Inc. director Gavin Hattersley reported equity award activity involving restricted stock units (RSUs) and common shares. On February 19, 2026, RSUs covering 1,619.3325 units were exercised and converted into 1,619 common shares of Zoetis common stock at a stated price of $0.00 per share.
Following this conversion, Hattersley directly held 3,835 common shares, then disposed of 481 shares back to Zoetis in exchange for cash based on the closing share price of $127.28 per share, leaving 3,354 common shares held directly. The filing also shows a holding of 1,936 RSUs granted under the Zoetis Inc. Amended and Restated 2013 Equity and Incentive Plan, each RSU representing a contingent right to receive one Zoetis common share upon vesting on its stated first-anniversary dates, subject to continued service and certain early vesting conditions.